Results 131 to 140 of about 3,564 (173)

L467F;F508del Complex Allele in a Heterozygous State with CFTRdele2,3: What to Expect from CFTR Modulators? [PDF]

Int J Mol Sci
Kondratyeva E, Efremova A, Melyanovskaya Y, Krasnova M, Milovanov M, Shchagina O, Stepanova A, Voronkova A, Sherman V, Kutsev S, Goldshtein D.   +10 more
europepmc   +1 more source

Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. [PDF]

J Cyst Fibros
Green N, Vu P, Xie J, Schwarzenberg SJ, Freedman S, Narkewicz M, Pittman J, Ratjen F, Rosenfeld M, Pope C, Duong J, Hoffman L, Heltshe S, Lusman SS, PROMISE Study Group.   +14 more
europepmc   +1 more source

The European Medicines Agency's review of elexacaftor/tezacaftor/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I <i>CFTR</i> variants. [PDF]

Eur Respir J
Drai C, van der Woude HJ, Lexmond AJ, van den Hoorn T, Mol PGM, Leacy FP, Przybyszewska A, Sepodes B, Castelnovo T.   +8 more
europepmc   +1 more source

People with cystic fibrosis with high sputum neutrophil elastase on elexacaftor-tezacaftor-ivacaftor exhibit worse pulmonary function and pro-inflammatory airway milieu. [PDF]

Sci Rep
Cammarata-Mouchtouris A, Giraldo DM, Collins GL, Parrilla MM, Kim SO, Mansour S, Giacalone VD, Cottrill KA, Tirouvanziam R, Chandler JD.   +9 more
europepmc   +1 more source

Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study. [PDF]

J Clin Med
Salvatore D, Campagna G, Padoan R, Pepe A, Amato A, Salvatore M.   +5 more
europepmc   +1 more source

Functional Rescue of CFTR-Dependent Transport in a Pancreatic Ductal Epithelial Cell Model: The Impact of Pharmacological Modulation and Inflammation. [PDF]

Int J Mol Sci
Ludovico A, Battistini M, Baroni D.
europepmc   +1 more source

Impact of COVID-19 and CFTR Modulators on Cystic Fibrosis: A Real-World Analysis of Care Patterns. [PDF]

Pediatr Pulmonol
Hinton AC, Sears EH, Lopez-Pintado S, Zuckerman JB.   +3 more
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Quality of Life in Children With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kümmerli S, Elviro CF, Regamey N, Mornand A, Faouzi M, Rochat I, Blanchon S.   +6 more
europepmc   +1 more source

Quantitative Systems Toxicology Predicts Ivacaftor-Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity. [PDF]

Clin Pharmacol Ther
Shi A, Cornwell C, Yang K, Beringer PM.
europepmc   +1 more source

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]

Ann Am Thorac Soc
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM, PROMISE Study Group .   +15 more
europepmc   +1 more source